[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
$otsky
Breaking: TD Cowen and Raymond James reiterate Buy ratings on $VERA with price targets of $XX and $XX respectively, citing positive clinical data and favorable market entry for related treatments. $OTSKY is mentioned in relation to these developments.
About $otsky
$otsky is a digital asset and blockchain project.
Insights
- $otsky mentions is up XX% from the previous week.
Engagements: XXX (24h)
Engagements 24-Hour Time-Series Raw Data
Current Value: XXX
Daily Average: XXX
X Week: XXXXX -XX%
X Month: XXXXXX +411%
X Months: XXXXXX -XX%
X Year: XXXXXXX +589%
1-Year High: XXXXXX on 2025-02-03
1-Year Low: X on 2024-12-26
Engagements by network (24h): X: XXX
Mentions: XX (24h)
Mentions 24-Hour Time-Series Raw Data
Current Value: XX
Daily Average: X
X Week: XX +20%
X Month: XX -XX%
X Months: XXX +103%
X Year: XXX +184%
1-Year High: XX on 2025-10-26
1-Year Low: X on 2024-12-15
Mentions by network (24h): X: XX
Creators: X (24h)
Creators 24-Hour Time-Series Raw Data
X unique social accounts have posts mentioning $otsky in the last XX hours which is down XX% from X in the previous XX hours
Daily Average: X
X Week: X no change
X Month: X -XX%
X Months: XX +21%
X Year: XX +100%
1-Year High: XX on 2025-06-25
1-Year Low: X on 2024-12-15
The most influential creators that mention $otsky in the last XX hours
| Creator | Rank | Followers | Posts | Engagements |
|---|---|---|---|---|
| @Quantumup1 | X | XXXXX | X | XXX |
Sentiment: XXX%
Sentiment 24-Hour Time-Series Raw Data
Current Value: XXX%
Daily Average: XX%
X Week: XXX% no change
X Month: XXX% no change
X Months: XXX% no change
X Year: XXX% +10%
1-Year High: XXX% on 2025-01-15
1-Year Low: XX% on 2025-09-12
Most Supportive Themes:
- Creator Activity Surge: (33%) The number of active creators mentioning $otsky has seen a significant increase, indicating growing interest and participation from content creators.
- Engagement Growth: (33%) While current engagements are low, the 1-year growth of XXX% suggests a strong historical engagement trend for $otsky.
- Mention Volume Increase: (33%) Mentions of $otsky have surged by 1080% month-over-month, pointing to a rapid increase in public discourse and awareness.
Most Critical Themes:
Top $otsky Social Posts
Top posts by engagements in the last XX hours
Showing only X posts for non-authenticated requests. Use your API key in requests for full results.
"TD Cowenthe PT on $VERA to $XX from $XX and reiterated at a Buy rating. $TVTX $OTSKY JBIO VRTX ABBV ALNY IONS Here's what TD Cowen had to say: We are increasing our estimated gross annual pricing for ataci' in IgAN to $350K based on new comparator product pricing increasing our PT to $XX based on higher peak US sales of $1.64B in 2033. Mgmt said Ph2 ataci' PIONEER IgAN/pMN/FSGS-data may come in 1Q26. VERA may pursue a monthly sNDA path as the formulation is the same as weekly. A June/July PDUFA is likely for weekly dosing in IgAN"
X Link @Quantumup1 2025-12-05T15:07Z 3928 followers, 1360 engagements
"Raymond James reiterated $VERA Strong Buy/$73 $OTSKY $TVTX JBIO VRTX ABBV ALNY IONS Raymond James said in its note: Pricing data for atacicept's competitor in the IgAN space sibeprenlimab (Voyxact) has been disclosed and it's at the top of the range we have been hearing (if not higher) from buyside investors over the last several weeks. The $30K per Q4W treatment WAC price ($390K annualized WAC assuming XX treatments per year) is roughly double the pricing assumption in our model for atacicept ($195K annualized WAC) which now looks almost absurdly conservative. Given the broad label Voyxact"
X Link @Quantumup1 2025-12-02T21:08Z 3928 followers, 3570 engagements
"In crowded kidney disease space Otsuka receives FDA approval for first-in-class Voyxact $OTSKY #pharma #KidneyDisease #FDA"
X Link @Alpha_Bronze 2025-12-01T14:30Z 7533 followers, XX engagements
"H.C. Wainwright reiterated $VERA Buy-$90 and saidOn November XX the FDA granted accelerated approval (AA) to sibeprenlimab marketed as Voyxact by Otsuka ( $OTSKY; not rated) for the treatment of adults with primary immunoglobulin A nephropathy (IgAN). $TVTX NVS JBIO VRTX ABBV ALNY IONS H.C. Wainwright addedThis approval was highly anticipated given that sibeprenlimab achieved the primary endpoint of reduction in urine protein creatinine ratio (UPCR) in the ongoing Phase X VISIONARY study. One highlight from sibeprenlimab's AA label is the absence of a UPCR cutoff to define IgAN patients "at"
X Link @Quantumup1 2025-11-28T12:11Z 3927 followers, 5234 engagements